Linagliptin Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 5 mg
Reference Brands: Tradjenta®(EU & US)
Category:
Diabetes
Linagliptin is a DPP-4 inhibitor that increases incretin levels, enhancing insulin secretion and lowering glucagon in a glucose-dependent manner. Benefits include improved glycemic control, low hypoglycemia risk, once-daily dosing, and weight neutrality. Approved in both the USA and EU, it's suitable as monotherapy or in combination therapy.
Linagliptin Tablets is available in Tablets
and strengths such as 5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Linagliptin Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Linagliptin Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Linagliptin tablets are approved for the treatment of type 2 diabetes in both the USA and EU. In the USA, they are marketed as Tradjenta®, approved via a New Drug Application (NDA) and regulated under 21 CFR, with labeling for risks like pancreatitis and joint pain. Manufacturers must ensure GMP compliance and implement post-marketing surveillance. In the EU, Linagliptin is authorized as Trajenta® via the centralized procedure, requiring CTD-format submission, a Risk Management Plan (RMP), PSURs, and full pharmacovigilance. For regulatory support, dossier preparation, or B2B sourcing, visit PharmaTradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing